CRISPR-Edited TILs Fight Advanced Colorectal Cancer in Patients
Although immunotherapeutic strategies have made huge strides in treatment for solid tumors, the promising results have not moved over into the treatment of gastrointestinal cancer. Now, a first-in-human clinical trial shows encouraging signs of safety and potential effectiveness of a CRISPR/Cas9 gene-editing technique to help TILs fight advanced colorectal cancer.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed